
NVIDIA's Third Growth Curve: Three Businesses Not Yet Visible in Its Financials
Autonomous driving, AI drug discovery, and robotics—three businesses grouped under the Edge Computing segment—accounted for just 7.5% of NVIDIA's revenue in FY27Q2 and contributed virtually nothing to EPS over the past two years, yet they will determine its valuation multiple beyond FY2030. This article values each business through an options framework while taking an unvarnished view of AI drug development: zero approvals globally, even as NVIDIA has fully exited its stake in Recursion. The company selling the picks and shovels is not betting on the gold mine.


























































